Chicago – February 6, 2024 – Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering. Partners Div Gupta, Christina Roupas, Courtney Tygesson and Laurie Bauer led the Cooley team advising Alto.
Alto offered a total of 9,246,000 shares of common stock priced at $16 per share, which included the full exercise of the underwriters’ option to purchase an additional 1,206,000 shares. Alto’s common stock began trading on the New York Stock Exchange on February 2, 2024, under the ticker symbol ANRO.
Cooley previously advised Alto on its $45 million Series C financing in November 2023.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.